Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials

QR Code

Long-term safety evaluation of bimatoprost ophthalmic solution 0.03%: a pooled analysis of six double-masked, randomized, active-controlled clinical trials

David Wirta1, Amanda M VanDenburgh2, Emily Weng3, Scott M Whitcup4, Sef Kurstjens5, Frederick C Beddingfield III4,61Private Practice, Newport Beach, CA, USA; 2Clinical Development, 3Biostatistics, 4Research and Development, 5Global Drug Development, Allergan, Inc, Irvine, CA, USA; 6Department of Med...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Wirta D, VanDenburgh A, Weng E, Whitcup S, Kurstjens S, Beddingfield F 3rd
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2011
Sujets:	Ophthalmology RE1-994
Accès en ligne:	https://doaj.org/article/426dcbdab9104b9089a9f1ff9b7ba3f1
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
par: Shafiee A, et autres
Publié: (2013)

Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits
par: Abayomi B Ogundele, et autres
Publié: (2010)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events
par: Tsumura T, et autres
Publié: (2012)

Bimatoprost ophthalmic solution 0.03% lowered intraocularpressure of normal-tension glaucoma with minimal adverse events [Corrigendum]
par: Tsumura T, et autres
Publié: (2013)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]
par: Tsumura T, et autres
Publié: (2013)

Aqueous humor penetration of topical bimatoprost 0.01% and bimatoprost 0.03% in rabbits: response to authors
par: Chang-Lin J-E, et autres
Publié: (2011)

Effects of treatment with bimatoprost 0.03% for 3 years in patients with normal-tension glaucoma
par: Inoue K, et autres
Publié: (2014)

An evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects
par: Borchert M, et autres
Publié: (2016)

Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%)
par: Moataz E Gheith, et autres
Publié: (2008)

In vivo comparative study of ocular vasodilation, a relative indicator of hyperemia, in guinea pigs following treatment with bimatoprost ophthalmic solutions 0.01% and 0.03%
par: Abayomi B Ogundele, et autres
Publié: (2010)

Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
par: Pfennigsdorf S, et autres
Publié: (2016)

Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
par: Pillunat LE, et autres
Publié: (2016)

Evaluating intraocular pressure-lowering solutions for the treatment of open-angle glaucoma: comparison between bimatoprost 0.03% and bimatoprost 0.01% – an observational switch study
par: Deshpande SS, et autres
Publié: (2017)

Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials
par: Myers JS, et autres
Publié: (2014)

Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy
par: Schnober D, et autres
Publié: (2015)

Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution
par: Lee D, et autres
Publié: (2017)

Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials
par: Wirta DL, et autres
Publié: (2021)

Si0.97Ge0.03 microelectronic thermoelectric generators with high power and voltage densities
par: Ruchika Dhawan, et autres
Publié: (2020)

COMPARATIVE EVALUATION OF TACROLIMUS 0.03% OINTMENT VS OLOPATADINE 0.2% EYE DROPS IN THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS
par: Hassan Sajjad Rathore, et autres
Publié: (2021)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications
par: Shen J, et autres
Publié: (2017)

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications [Corrigendum]
par: Shen J, et autres
Publié: (2018)

Randomized, Double-Masked, Placebo-Controlled Dose Escalation Study of TAK-639 Topical Ophthalmic Solution in Subjects with Ocular Hypertension or Primary Open-Angle Glaucoma
par: Martin P, et autres
Publié: (2020)

Bimatoprost in the treatment of eyelash hypotrichosis
par: Simon K Law
Publié: (2010)

Improved electrochemical properties of LiNi0.91Co0.06Mn0.03O2 cathode material via Li-reactive coating with metal phosphates
par: Kyoungmin Min, et autres
Publié: (2017)

Generation of heterozygous (MRli003-A-1) and homozygous (MRli003-A-2) MYH10 knockout human iPSC lines
par: Fangfang Zhang, et autres
Publié: (2021)

Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions
par: Campbell JH, et autres
Publié: (2014)

Is Interferon α-2b 1 MillionIU/mL Truly Better Than Tacrolimus 0.03% for Steroid-Resistant VKC ?: Our 2-Year Experience at a Tertiary Health-Care Centre
par: Gupta S, et autres
Publié: (2021)

Effect Of Intracameral Phenylephrine And Ketorolac 1.0%/0.3% On Intraoperative Pain And Opioid Use During Cataract Surgery
par: Donnenfeld ED, et autres
Publié: (2019)

Periorbital muscle atrophy associated with topical bimatoprost therapy
par: Wang PX, et autres
Publié: (2014)

Role of prostaglandins and specific place in therapy of bimatoprost in the treatment of elevated intraocular pressure and ocular hypertension: A closer look at the agonist properties of bimatoprost and the prostamides
par: Scott D Smid
Publié: (2009)

Hyperthermia mediated by dextran-coated La0.7Sr0.3MnO3 nanoparticles: in vivo studies
par: Haghniaz R, et autres
Publié: (2016)

Treatment with bimatoprost for exophthalmos in patients with inactive thyroid-associated ophthalmopathy
par: Higashiyama T, et autres
Publié: (2018)

Ophthalmic epidemiology
Publié: (1994)

Ophthalmic genetics
Publié: (1994)

Ophthalmic research
Publié: (1970)

RPM 03 de Febrero 1998
par: Banco Central de Chile
Publié: (2020)

Temperature-dependent and time-dependent effects of hyperthermia mediated by dextran-coated La0.7Sr0.3MnO3: in vitro studies
par: Haghniaz R, et autres
Publié: (2015)

Safety of besifloxacin ophthalmic suspension 0.6% as a prophylactic antibiotic following routine cataract surgery: results of a prospective, parallel-group, investigator-masked study
par: Malhotra R, et autres
Publié: (2012)

Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension
par: Bruce I Gaynes, et autres
Publié: (2008)

Iris and periocular adverse reactions to bimatoprost in Japanese patients with glaucoma or ocular hypertension
par: Inoue K, et autres
Publié: (2012)